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Multiple myeloma (MM) is a hematologic cancer character-
ized by the accumulation of malignant plasma cells in the
bone marrow, which causes bone destruction and marrow
failure [1]. Despite the fact that clinical introduction of novel
drugs has led to a dramatic improvement of disease, MM
ultimately relapses and remains an incurable disease [2].
Consistently, research in this field has dramatically grown, as
demonstrated by the increased rate of publications during the
last decade. Original research and review articles published
in this special issue focus on identification of new targets
and pathways for prognostic and therapeutic application in
myeloma, as well as validation of novel antitumor agents.
(1) Diagnosis, Monitoring, and Prognosis of MM. Extensive
gene expression profile analysis has provided interesting
insight into the disease biology, and its correlation with
clinical outcome has opened a new direction for risk strat-
ification as well as novel target and therapy identification.
Prognostic models such as the Durie-Salmon staging system
and International Staging System (ISS) are available and
account for the disease burden [3]; however, the original
analysis of ISS system did not include Chinese patients’ data
and take into account the recent introduction of novel agents.
The data provided in the manuscript by J. Lu et al. represent
the first multicenter retrospective study analyzing ISS value
in a large number of unselected Chinese myeloma patients.
The results demonstrate that ISS still has prognostic value
in Chinese patients with MM, but not in patients receiving
bortezomib-based therapy. Therefore, further studies are
needed to develop more suitable and robust stratification
systems to predict prognosis and optimize treatment strategy
early during the course of the disease.
Minimal residual disease (MRD) has emerged as one of
the most relevant prognostic factors in MM and should be
included in a new definition of complete response (CR) [4].
In the manuscript by M. Fulciniti et al., the authors reviewed
current definition of deep response in MM, advantages and
limitations of current MRD assessment assays, and clinical
evidences for MRD monitoring as a prognostic tool for
therapeutic decisions in MM, providing the rationale for
the use of MRD assessment in the evolving MM clinical
paradigm.
(2) Role of the Bone Marrow Milieu. The bone marrow (BM)
microenvironment plays a crucial role in MM pathogenesis.
MM cells reside in and dynamically interact with various
subsets of cells in the BM including mesenchymal cells
(MSCs), osteoclasts (OCLs), osteoblasts (OBLs), and vascular
endothelial cells, which support growth and survival of the
tumor cells and lead to development of drug resistance [5].
These cells not only physically interact withMMcells but also
secrete growth and/or antiapoptotic factors. The cross talk
between MM cells with bone marrow stromal cells or other
cellular components is finely tuned by a plethora of cytokines,
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growth-factor, and other molecules which can be released
either by MM cells or by cells of the BM microenvironment.
Several studies have demonstrated deregulation of the cellular
and humoral components of the BM in MM including
increased OCL activity and inhibited OBL activity, and both
are involved in the pathophysiology of the bone lesions in
MM [6].
The review by F. Accardi et al. summarizes the preclinical
and clinical evidence on the effects of bortezomib and other
new Proteasome Inhibitors (PIs) on myeloma bone disease.
Osteoclastic formation and activity are inhibited by PIs,
mainly through the blockade of RANKL signaling pathway
in the osteoclast progenitors. However, the more significant
impact of the bone remodeling by this class of drugs is the
capacity to stimulate either the osteogenic differentiation
of MSC or the osteoblastic function, leading to the conse-
quent bone formation with a considerable anabolic effect.
Osteocytes are also possible targets of PIs with a stimulatory
effect on their viability. The preclinical evidence, thus, is
confirmed in MM patients treated with bortezomib and
more recently with carfilzomib. An improvement of the bone
remodelingmarkers was observed in the patients treatedwith
PIs.Thehistomorphometric data inMMpatients treatedwith
bortezomib prominently indicated that PIs can stimulate the
bone formation process and induce the bone regeneration
process. Bone healing, as well as an increase in the BMD,
has also been reported in some of the patients treated with
bortezomib. Overall, the literature data support the use of
these drugs to restore bone integrity in MM patients.
MM cells are cradled within the BM microenviron-
ment by an array of adhesive interactions between the BM
extracellular matrix (ECM) components and a variety of
adhesionmolecules on the surface of MM cells, which results
in the “cell adhesion-mediated drug resistance” (CAM-DR)
thought to be one of the major mechanisms by which MM
cells escape the cytotoxic effects of therapeutic agents [7].
MM is characterized by continuous spread of cancer cells at
different sites of the bone marrow, through continuous cell
trafficking including adhesion of myeloma cells to vascular
wall. This process requires the presence of P-selectin on
the endothelium and stroma, as well as PSGL-1 on tumor
cells. PSGL-1 was previously suggested as a novel target
for immunotherapy in MM using small molecule inhibitor
which demonstrated sensitization of MM cells to therapy,
controlling tumor growth and dissemination. However, poor
pharmacokinetic profile with a very short half-life may hold
up further usage of this drug in MM. The study by B.
Muz et al. demonstrates that inhibition of P-selectin/PSGL-1
axis using humanized monoclonal antibodies is a promising
approach for the treatment of MMwith high efficacy in inhi-
bition of P-selectin/PSGL-1 interactions and sensitization of
MM cells to therapy, along with favorable pharmacokinetics.
Angiogenesis is fundamental to tumor growth and spread
in many hematological disorders, particularly MM [8]. The
angiogenic potential of MM is regulated by several pro-
and antiangiogenesis cytokines produced by myeloma cells
and other cell types in the tumor microenvironment. The
study by T. Valkovic´ et al. determines the plasma levels of
monocyte chemotactic protein-1 (MCP-1), as well as its
possible associationwith angiogenesis, in 45 newly diagnosed
MMpatients and 24 healthy controls.Themanuscript reveals
a positive association between plasma MCP-1 levels, angio-
genesis, and clinical features in patients with MM. However,
additional prospective studies with a respectable number of
patients should be performed to authenticate these results
and establish MCP-1 as a possible target of active treatment.
(3) Genetic and Epigenetic Abnormalities. MM cells accu-
mulate various genetic and epigenetic abnormalities that
drive the malignant phenotype and confer distinct biologic
sequelae and disease outcomes [9].
miRNA are important transcriptome modifiers that play
important role in myeloma tumor progression, survival,
and development of drug resistance [10]. In their review,
Raimondi et al. discuss the role of endogenous noncoding
RNAs as microRNAs as a novel class of regulators of the
intercellular communication between MM cells and other
cells of the BM milieu, focusing on the therapeutic potential
of experimental strategies aimed at modulating microRNA
levels in MM cells and capable of overcoming the tumor-
promoting BMmicroenvironment.
Moreover, S.-F. Lin and W.-C. Yang review molecular
mechanisms underlying MM development, progression, and
resistance to treatment, further highlighting the relevance
of microRNAs as well as immune dysfunctions and con-
ventional or novel therapies targeting such vulnerabilities.
Overall, authors advocate that understanding the genomic
landscape of MM deserves more attention in the prospect of
developing personalized and effective targeted therapies that
overcome resistance to currently used anti-MM drugs.
In addition tomicroRNAs, dysregulation of transcription
factors (TFs) features prominently in the biology of MM
and B cell malignancies. TFs are the downstream effectors
of signaling pathways within cells, which receive growth and
other signals from the microenvironment; they also regulate
cellular homeostasis as well as cell survival and proliferation.
On this basis, mutations in TF genes or dysregulation of TFs’
expression could play a significant role in cancer pathogenesis
and drug resistance. The TF EBF1 is the master regulator
of the specification, development, and maintenance of the
B-lymphoid lineage, and perturbations of EBF1 expression
and/or functions have been associated with the development
of B cell malignancies [11]. In this regard, M. Mesuraca et al.
have reviewed the role of two zinc finger proteins, namely,
ZNF423 and ZNF521, as potent inhibitors of EBF1 and as
likely contributing to the development of B cell leukaemia
diseases.
Genome instability, defined by higher rate of genomic
changes acquisition per cell division compared to normal
cells, represents a prominent feature of MM cells [12]. M.
Cea et al. provide a comprehensive overview of the current
knowledge of genomic instability in MM both in terms of its
contribution to disease development and progression and in
terms of possible relevance as therapeutic target. The paper
describes mechanisms by which genetic aberrations give rise
to multiple pathogenic events required for myelomagenesis
and concludes with a discussion of the clinical applications
of these findings in MM patients.
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Altogether, the data presented in this special issue may
contribute to increasing our current knowledge of the biology
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